MVEN yields 17547.44% · PFE yields 6.13%● Live data
📍 MVEN pulled ahead of the other in Year 1
Combined, MVEN + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MVEN + PFE for your $10,000?
TheMaven, Inc. operates a technology platform in the United States. The company operates the Maven platform, an online publishing platform consisting of publishing tools, video platforms, commenting features, social distribution channels, newsletter technology, machine learning content recommendations, notifications, and other technology that delivers various features to drive a digital media business in cloud-based suite of services that provides owned and operated media businesses, Publisher Partners, and individual creators the ability to produce and manage editorially focused content through tools and services. It develops advertising technology, techniques, and relationships that allow its publisher partners and expert contributors to monetize online editorially focused content through various display and video advertisements tools and services for driving a subscription or membership-based business and other monetization services. It also operates a coalition of professionally managed online media channels on third party cloud platforms and data center hosting facilities. The company's Publishing Partners publish content and oversee an online community for their sites and leverages its technology platform to engage the collective audiences within a single network. TheMaven, Inc. was incorporated in 1990 and is based in New York, New York.
Full MVEN Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.